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Anti-inflammatory and Anti-apoptotic Potentials of Apigenin
against Liver Injury Induced by Ischemia-Reperfusion in Rats
Hala F. Zaki, Rania M. Abdelsalam, Dalia M. El-Tanbouly, Aya M. Zaki
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University

ABSTRACT

Apigenin is a dietary flavonoid that exists copiously in several herbs and vegetables. It exhibits anti-inflammatory, antimutagenesis, anti-proliferative and antioxidant properties. The present work aimed to investigate some of mechanisms
underlying protective potential of apigenin in hepatic ischemia-reperfusion injury. Rats were divided into four groups;
sham-operated, sham-operated pretreated with apigenin (25 mg/kg, p.o.), ischemia/reperfusion (I/R) (30 min ischemia
and 1 h reperfusion) and I/R pretreated with apigenin. Compared with I/R group, pretreatment with apigenin markedly
reduced transaminases levels and ameliorated tissue histopathological changes. Apigenin significantly reduced high mobility
group box 1 (HMGB1) expression and suppressed liver tumor necrosis factor- α (TNF-α), nuclear factor κB (NF-κB) and
myeloperoxidase (MPO) activity. Moreover, apigenin restored reduced glutathione (GSH), decreased liver lipid peroxidation,
and boosted glutathione peroxidase (GPx) activity in addition to attenuation of apoptosis by increasing Bcl-2/Bax ratio. It
may thus be concluded that inhibition of HMGBI by apigenin plays a role towards its antioxidant, anti-inflammatory as well
as anti-apoptotic properties which are involved in conferring its hepato-protective properties
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1. INTRODUCTION

pro-inflammatory cytokines such as interleukin-2 (IL-2),
interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α)
and damage associated molecular patterns (DAMPs) such
as high mobility group box-1 (HMGB1)[14]. HMGB1 then
creates a positive feedback circuit causing the release
of extra chemokines and cytokines. Thus, under stress,
HMGB1 endures a continuing inflammatory state[15].
Apigenin, naturally is present as a dimer, biapigenin,
isolated mostly from the flowers and buds of Hypericum
perforatum[16]. It abundantly exists in common vegetables
and fruits as grapefruit, parsley, plant-derived beverages,
oranges, tea, onions, wheat sprout and chamomile[17].
Apigenin exerts anti-inflammatory, anti-mutagenesis, antiproliferative and antioxidant activities[18,19,20]. It has been
known as a cancer chemopreventive agent. It is a cell cycle
inhibitor[21], having low intrinsic toxicity on normal versus
cancer cells[22]. Apigenin activates nuclear factor erythroidrelated factor-2 (Nrf2), that induces the transcriptional
activity of the antioxidant response element (ARE)
which is crucial for induction of genes encoding many
cytoprotective enzymes as heme oxygenase-1(HO-1) and
glutathione peroxidase (GPx)[23,24,25,26].
The aim of the current investigation was to evaluate
the possible hepatoprotective activity of apigenin against
hepatic injury associated with I/R. It is also extended to
gain convincing insights into its putative underlying
mechanism.

In liver surgery, prolonged periods of interrupting blood
supply with subsequent lacking of nutrients and oxygen
may occur during transplantation, removal of liver tumors,
vascular reconstruction and trauma[1,2,3]. Shortly after blood
flow restoration, there is an upsurge in injury instigated by
ischemia, exacerbating the global damage, which is mainly
attributed to the excessive triggering of innate immune
response[4,5,6].
The response in reperfusion comprises two successive
phases. Immediately after reperfusion, sudden reoxygenation provokes reactive oxygen species (ROS)
generation which induce oxidative imbalance and
stimulate Kupffer cells (KC) in the liver[7,8]. Meanwhile,
levels of nitric oxide (NO) are reduced and there is an
imbalance between endothelin-1 and NO production,
leading to vasoconstriction and entrapment of platelets and
neutrophils[9]. Hepatocyte injury is then promoted through
necrosis and apoptosis[10,11,12]. In the late phase of reperfusion
there is a further activation and recruitment of neutrophils,
T helper cells, and platelets to the liver. Permanence of
theses inflammatory cells in the constricted sinusoids
results in inflammatory damage and microvasculature
collapse[13]. Activation of KC, neutrophils, and platelets
results in a massive local production of ROS as well as
a cascade of inflammatory events including release of
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2. MATERIAL AND METHODS
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was used to estimate liver contents of nuclear factor κB
(NF-κB), TNF-α, myeloperoxidase (MPO) activity and
oxidative stress biomarkers. NF-κB and TNF-α were
determined using rat specific ELISA kits (Wuhan Eiaab
science, Wuhan, China) and (RandD, USA), while MPO
was measured as described by Bradley et al[29]. The
method depends on the oxidation of dianisidine by MPO
resulting in the formation of a compound exhibiting an
increased absorbance at 460 nm. The selected oxidative
stress biomarkers in the liver were glutathione peroxidase
(GPx), reduced glutathione (GSH) and thiobarbituric acid
reactive substances (TBARS). GPx was measured using a
specific kit obtained from Oxis Research (Oxford, USA),
while GSH and TBARS were measured colorimetrically
in the homogenate using specific kits obtained from
Biodiagnostic Co (Cairo, Egypt) as described by
Beutler et al[30] and Ohkawa and Ohishi[31], respectively.

2.1. Animals
Adult male Wistar albino rats, each weighing
200±20 g, were purchased from the National Research
Centre in Cairo and housed at a temperature of (23 ± 2oC)
and a relative humidity of (60 ± 10%). They were kept
on a standard pellet chow and allowed water ad libitum.
The Ethical Committee for animal Experimentation at the
Faculty of Pharmacy, Cairo University approved the study
(Permit number: 1273).
2.2. Drugs and chemicals
Dimethyl sulfoxide (DMSO) and apigenin were
purchased from Sigma–Aldrich Chemicals (St. Louis,
MO, USA).
2.3. Induction of hepatic I/R injury

Since the above parameters had to be represented
per mg protein liver tissue, the protein content of the
homogenate was determined according to the method
described by Bradford[32].

After anesthetizing the animals with thiopental sodium
(50 mg/kg, i.p)[27], an upper abdominal midline incision
was made to expose the common hepatic artery and portal
vein. These were then clamped for 30 min to induce
hepatic ischemia, then reperfusion was allowed for 1h[28]
and designed as “ischemia/reperfusion” (I/R) rats.

Western Blotting analysis of HMGB1
20 µg protein concentration of each sample was first
loaded on a polyacrylamide gel then transferred onto
polyvinylidene difluoride membranes (Thermo Fischer
Scientific, MA, USA). A blocking buffer consisting
of 20 mM Tris-Cl, pH 7.5, 150 mM NaCl, and 0.1%
Tween 20 and 3% bovine serum albumin (BSA) was
then added to the membranes for 1 hour to prevent
nonspecific binding of the antibodies before incubating
them overnight at 4 °C with HMGB1 or with Beta actin
(β- actin) primary antibodies (Thermo Fisher Scientific,
MA, USA). Secondary antibodies conjugated to horseradish peroxidase (Thermo Fisher Scientific, MA, USA)
were then added to the membrane for 1 h at 37 °C followed
by the chemiluminescent substrate (ClarityTM Western
ECL substrate - BIO-RAD, USA). Band intensity was
then analyzed by Chemi Doc ™ imaging system with
Image Lab ™ software version 5.1 (Bio-Rad Laboratories
Inc., Hercules, CA, USA). The results were normalized to
β-actin.

2.4. Experimental design
The study was carried out both on I/R rats and on shamoperated animals where rats were exposed to laparotomy
but without undergoing ischemia/ reperfusion.
Four groups of 10 rats each were allocated as follows
Groups 1and 2: Sham-operated rats. Animals were
given either 0.1% v/v DMSO (1 ml/kg) or apigenin
(25 mg/kg) respectively orally for 5 days before being
sham-operated.
Groups 3 and 4: I/R rats. Animals were treated as
above with either DMSO or apigenin for 5 days before
being subjected to I/R.
Blood samples were then collected from the retroorbital sinus for plasma preparation before subjecting the
animals to euthanasia by decapitation under anesthesia.
The liver of all animals was removed, and divided into four
segments.

Quantitative real time PCR analysis of Bax and Bcl-2
gene expression

One segment was used to prepare a 10% homogenate in
ice-cold saline, one was used for histological examination,
one for Western blot analysis, and one for quantitative real
time PCR (qRT PCR).

A specific extraction kit (Qiagen, Germantown, MD,
USA) was used to extract total RNA from liver homogenate,
which was then quantified spectrophotometrically at 260
nm. Equal amounts of extracted RNA were then reverse
transcribed into cDNA using high capacity cDNA reverse
transcription kit (Thermo Fischer Scientific, MA, USA).
To assess the gene expression of Bax and Bcl-2, qRTPCR was performed using an ABI PRISM 7500 fast
sequence detection system (Applied Biosystems, CA,
USA). The sequences of PCR primer pairs used were the
following. For Bax, F:5’- CCCTGTGCACTAAAGTGCCC -3′, R: 5′- TTCTTCACGATGGTGAGCG-3′, for
Bcl-2
F:5’-CTACGAGTG-GGATGCTGGAGG-3′,

2.5. Biochemical measurements
2.5.1 Determination of relevant parameters in plasma
The separated plasma was used to assess liver functions
by determination of the enzymes, alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) using suitable
kits (Biodiagnostic Co, Cairo, Egypt).
2.5.2. Determination of relevant parameters in liver tissue
The 10 % liver homogenate prepared in ice-cold saline
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R:5′ GTCAGATGGACACATGGTG -3′ and for
β-actin F: 5′-TGCTGGTGCTGAGTATGTCG-3′, R:
5′-TTGAGAGCAATGCCAGCC-3′.

standard error (SEM) then subjected to one way analysis
of variance (ANOVA) followed by Tukey-Kramer test for
multiple comparisons. Statistical analysis was done using
GraphPad Prism software (version 6; GraphPad Software,
Inc., San Diego, CA, USA).

The relative expression of target genes was obtained
using the 2−ΔΔCT formula as described by Livak and
Schmittgen[33], using β-actin as a housekeeping gene.

3. RESULTS

2.6. Histopathological evaluation

3.1. Effect of apigenin on aminotransferases activities

Transverse 4µm sections of liver specimens fixed in
10% formalin were stained with hematoxylin and eosin
(H and E) and examined under a light microscope for
detection of histo-pathological changes.

A significant increase in the plasma aminotransferase
levels of rats subjected to I/R was shown, reaching 2.68
fold the sham-operated control group for AST and 1.45
fold the sham-operated control group for ALT. Treatment
with apigenin effectively guarded against this rise
(Fig.1 A and B).

2.7. Statistical Analysis
The biochemical results were represented as means ±

Fig.1: Changes in ALT (A) and AST (B) in the plasma of rats exposed to hepatic I/R injury after treatment with apigenin (AP).
Results are presented as means ± SEM of 8 rats and analyzed statistically using one-way ANOVA followed by Tukey-Kramer test for multiple comparisons.
Statistically significant differences (< 0.05) from sham-operated rats and from the I/R rats are denoted by a and b respectively.

3.2. Effect of apigenin on liver histopathology:

subjecting the rats to I/R led to dilation of the central and
portal veins as well as infiltration of inflammatory cells
within the tissue surrounding the bile duct. Pretreatment
with apigenin led to protection against these changes and
resulted in no histological changes (Fig.2).

The liver sections of sham-operated rats pretreated
with DMSO or apigenin showed no histological changes
of the portal area and surrounding hepatocytes. However,

Fig.2: Hepatic histological changes in rats exposed to I/R after treatment with apigenin (AP). Liver sections of sham-operated control rats pretreated with
DMSO (A) or apigenin (B) showed no histological changes of the portal area and surrounding hepatocytes. Dilation of the central and portal veins (large arrow)
as well as infiltration of inflammatory cells within the tissue surrounding the bile duct (small arrow) in rat exposed to I/R (C). Normal histological hepatocellular
architecture in I/R rats pretreated with apigenin (D) (HandE x 400). The livers of 4 rats from each group were used for detection of histopathological changes.
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3.3. Effect of apigenin on inflammatory biomarkers:
Subjecting rats to I/R induced a profound spike in
HMGB1 reaching 12.74 fold the sham-operated control
group and showed a statistically significant rise in MPO
activity as well as TNF-α and NF-κB contents. However,

Zaki et. al.

apigenin (25 mg/kg; p.o) impeded the noxious effect of
I/R on hepatic HMGB1, NF-κB and TNF-α by lessening
their liver contents to be 26.65%, 52.81% and 51.84%,
respectively. It also blunted the activity of MPO to 53.50%
(Fig 3 A, B, Cand D).

Fig.3: Changes in hepatic HMGB1 (A), TNF-α (B), NF-κB (C) and MPO activity (D) in rats exposed to hepatic I/R injury after treatment with apigenin (AP).
Results are presented as means ± SEM of 8 rats and analyzed statistically using one-way ANOVA followed by Tukey-Kramer test for multiple comparisons.
Statistically significant differences (< 0.05) from sham-operated rats and from the I/R rats are denoted by a and b respectively.

3.4. Effect of apigenin on oxidative stress biomarkers:

TBARS content that reached 1.79 fold the sham-operated
control group. Apigenin efficiently diminished hepatic
TBARS content to 66.33%, restored hepatic GSH content
to 278.95 % and enhanced the hepatic GPx activity to
278.95 %. (Fig 4 A, B and C).

The deterioration in oxidative status following I/R was
strongly evident by the obvious decline in both liver GSH
content and GPx activity as well as the marked elevation in

Fig.4: Changes in hepatic TBARS (A), GPx (B) and GSH (C) in rats exposed to hepatic I/R injury after treatment with apigenin (AP).
Results are presented as means ± SEM of 8 rats and analyzed statistically using one-way ANOVA followed by Tukey-Kramer test for multiple comparisons.
Statistically significant differences (< 0.05) from sham-operated control rats and from the I/R group are denoted by a and b respectively.
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3.5. Effects of apigenin on apoptotic biomarkers:

rise in Bax, indicating an increase in pro-apoptotic activity
(Fig.5). Conversely, apigenin enhanced greatly the gene
expression of Bcl-2 to 471.68 %, but dampened that of Bax
to19.61 %. (Fig 5 Aand B).

I/R injury led to a diminution in the gene expression of
Bcl-2, as a measure of anti-apoptotic activity, and a marked

Fig.5: Changes in hepatic mRNA expression of Bax(A), Bcl-2(B) and Bax/Bcl-2 ratio (C) in rats exposed to hepatic I/R injury after treatment with apigenin
(AP). Results are presented as means ± SEM of 8 rats and analyzed statistically using one-way ANOVA followed by Tukey-Kramer test for multiple
comparisons. Statistically significant differences (< 0.05) from sham-operated control rats and from the I/R group are denoted by a and b respectively.

4. DISCUSSION

Neutrophils stimulation with HMGB1 increases
their adhesive and migratory functions[44]. Furthermore,
HMGB1 stimulates neutrophils production of ROS[45] and
triggers the activation of NF-κB which further promotes
HMGB1 release by activated immune cells[46,47].

Pretreatment of rats with apigenin for five consecutive
days attenuated hepatic damage associated with I/R,
as revealed by the preserved structural integrity of the
hepatocellular membrane and liver cells architecture
in histopathological pictures along with the suppressed
plasma activities of liver transaminases (ALT and AST).
This is in agreement with Ali et al.[34] who reported the
protective effect of apigenin on N-nitrosodiethylamineinduced liver injury, where rats treated with various doses
of apigenin exhibited a dose-dependent decrease in the
levels of ALT and AST enzymes.

The anti-inflammatory effects of apigenin have
been revealed clearly in this study by the effective
decrease in the liver contents of NF-κB and the proinflammatory cytokine, TNF-α. This is in coherent with
Shukla et al.[48] who reported that apigenin suppressed
prostate carcinogenesis via inactivation of NF-κB pathway.
Sundry previous studies documented that apigenin
repressed NF-κB activity and consequently inhibited LPSinduced pro-inflammatory cytokines release by human
primary monocytes and macrophages[49,50]. Moreover,
pretreatment with apigenin decreased NF-κB protein
expression and TNF-α level in D-galactosamine/LPSinduced liver injury in rats[51].

Moreover, apigenin restored the elevated transaminases
activities following paracetamol-induced hepatotoxicity in
mice[35] and rats[36].
The present findings depicted the ability of apigenin to
normalize the expression of HMGB1 in liver. This effect was
coupled with prominent anti-inflammatory, antioxidant and
antiapoptotic activities. The effect of apigenin on HMGB1
may be ascribed to its previously reported capability
of up-regulating HO-1[25,26] which prevents the nuclear
translocation of HMGB1 and dampens its release[37,38,39].
HMGB1 is a typical DAMP that acts as an alarm in
mediating sterile inflammatory response due to I/R damage
in multiple tissues as liver[39]. It stimulates monocytes to
exhibit an increased capacity for adhesion[40] and release
multiple cytokines and inflammatory mediators[41,42,43].

Similarly, TNF- α was significantly decreased following
apigenin treatment in a mouse model of alcohol-induced
liver damage[52] and in different experimental models of
inflammatory bowel disease[53,54].
In addition, a significant decrease in MPO activity
was observed by apigenin treatment confirming its
potent anti-inflammatory effect and harmonizes with
Lampropoulos et al.[55] where apigenin reduced pancreatic
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MPO activity in experimental model of acute pancreatitis.
Moreover, administration of apigenin effectively
ameliorated neutrophil infiltration as evidenced by the
suppression of colonic MPO following acetic acid[56],
dextran sulphate sodium and trinitrobenzenesulfonic acidinduced colitis in rats[54].

Zaki et. al.

In conclusion, the present results provide profound
insights into the role of apigenin in mitigating hepatocellular
injury following I/R. It largely curbed the evoked oxidative
stress, inflammatory response and apoptotic cell death
throughout the reperfusion time.
CONFLICT OF INTEREST

The hepatoprotective effect of apigenin against
various hepatotoxins such as paracetamol[36] and
N-nitrosodiethylamine[34] was previously attributed to
its powerful antioxidant activity. The authors reported a
significant increase in the enzyme antioxidant defense
mechanisms along with a reduction of lipid peroxidation in
animals treated with apigenin.
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